Skip to main content
. Author manuscript; available in PMC: 2018 May 9.
Published in final edited form as: Cancer. 2015 Aug 26;121(23):4165–4172. doi: 10.1002/cncr.29636

Table 4.

Overall stage 1 and stage 2 tumor early progression and response

Primary endpoint N = 50 95% CI
Early progression (EP), n (%) 13 (26) (0.1, 0.4)
Progression-free at 9 weeks (PFS9w), n (%) 18 (36) (0.2, 0.5)
Neither EP nor PFS9w, n (%) 19 (38)

EP, disease progression or death within first 3 weeks (cycle 1).

PFS9w, alive without progression up to cycle 4 day 1 and beyond.